CTRI/2022/11/047029招募中未知
An open label, balanced, randomized, two treatment, two sequence, two period, crossover bioequivalencestudy of Lomustine 40mg capsules of Carnegie Pharmaceuticals, LLC, USA and Gleostine (Lomustine)40mg capsules of Corden Pharma Latina SPA in patients who are already receiving a stable dose ofLomustine
Carnegie Pharmaceuticals0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •Male patients and/or non-pregnant, non-lactating female subjects of child bearing potential and female patients who have attained menopause
- •Patients of age 18 years and above with BMI of 18.50 â?? 29.99 and weight more than 50 Kg.
- •Patients who are diagnosed with brain tumors and have underwent appropriate surgical and-or radiotherapeutic procedures or Hodgkins lymphoma and receiving a stable dose of Lomustine
- •Patients who are prescribed with at least 06 cycles of treatment on Lomustine and completed at least 01 cycle of treatment and have at least 02 cycles of treatment left before initiating the study
- •Patients whose life expectancy of greater than or equal to 3 months.
- •Patients with normal vital parameters, pulse rate and temperature and general clinical examination or those considered not clinically significant as decided by the investigator
- •Patients with no more than one line of chemotherapy
- •Patients with no current or recent treatment with another investigational drug
- •Patients with absence of any major cardiovascular disorder, including but not limited to: myocardial infarction, unstable angina within 6 months prior to randomization, New York Heart Association Grade II or greater congestive heart failure and arrhythmias
- •Patients with biochemical parameters including liver and kidney function as follows
- •Serum creatinine lesser than 2.0 times of upper normal limit
- •AST or ALT lesser than 2.5 times of upper normal limit
- •Alkaline phosphatase lesser than 1.5 times of upper normal limit
- •Normal or clinically insignificant ECG and chest X-ray.
- •Patients with normal or clinically insignificant pulmonary function tests as evaluated by the investigator with predictive forced vital capacity greater than 70 percent.
- •Negative pregnancy test for females and does not plan to become pregnant during course of the study and for 3.5 months after completion of study.
- •Patients who are willing to use one of the following acceptable methods of contraception during the study period and for at least 3.5 months after completion of study
- •Documented tubal sterilization
- •Intrauterine device (IUD) placed 7 days prior to Day 0
- •Hormonal method started at least 7 days prior to Day 0 plus one barrier method
- •Two barrier methods used together
- •Absolute sexual abstinence
- •Patients or legally acceptable representative who can give written informed consent and communicate effectively.
排除标准
- •History of uncontrolled systemic diseases such as cardiac, gastrointestinal, respiratory, hepatic, renal, endocrine, neurological, metabolic, psychiatric and hematological disorders, based on clinical investigatorâ??s judgment.
- •History of chronic alcoholism/ chronic smoking/ drug of abuse.
- •Patients with hypersensitivity to Lomustine or any of the excipients.
- •Pregnant or lactating female patient
- •History of consumption of tobacco containing products within 48 hours prior to proposed time of dosing
- •Patients who are positive for hepatitis B, anti-hepatitis C and human immunodeficiency virus (HIV 1&2).
- •Patients with known history of myelosuppression
- •Patients with known history of Pulmonary toxicity
- •Patients with known history of Nephrotoxicity
- •Present or past history of intake of drugs or any prescription drug other than the drugs already included in patientâ??s treatment regimen or over the counter (OTC) drugs within 14 days which potentially modify kinetics / dynamics of Lomustine or any other medication judged to be clinically significant by the investigator.
- •History of consumption of grapefruit and/or its products within 10 days prior to the start of study.
- •Patients who had not donated blood/had any other blood loss over 01 unit of blood during the last 03 months before study initiation.
- •History of consumption of one or more of the below, 48 hours prior to dosing: Xanthine containing food or drinks such as cola, chocolate, coffee or tea, citrus fruits or items (lime, lemon and orange), alcohol and any other food/beverage known to have interactions as deemed by the investigator.
- •Patients who are dysphagic.
研究者
相似试验
已完成
2 期
An open label, balanced, randomized, two treatment, two period, two sequence, cross over, comparative bioavailability study of a single dose of commercially available 6 gm Curcumin hard gelatin capsules (each capsule contains 500 mg of Curcumin 95%) and 6 gm Curcumin soft gelatin capsules (each capsule contains 750 mg of Curcumin 95%) of Amsar Private Limited, in healthy human adult male subjects under fed condition.CTRI/2009/091/000327Amsar Private limited30
已完成
不适用
A Bioequivalence study to compare the Bioequivalence of two formulation of quetiapine in schizophrenic patients.CTRI/2010/091/000181Dr Reddys Laboratories Ltd India54
已完成
不适用
A Bioequivalence study of two formulations of Quetiapine film coated tablets in adultschizophrenic patientsCTRI/2012/05/002632Hetero Labs Limited54
招募中
不适用
Bioequivalence study ofCapecitabine tablets 500 mgCTRI/2018/05/014342Mega Pharma SA
已完成
不适用
A study to evaluate the bioequivalence of Quetiapine with Seroquel in adult schizophrenic patients.CTRI/2010/091/000001Intas Pharmaceuticals Ltd48